Compare up to 4 stocks side by side, across all 7 of StockIQ's scoring categories.
| Category | XLO Xilio Therapeutics, Inc. | AAPG Ascentage Pharma Group International - American Depository |
|---|---|---|
| Price | $9.05 +1.3% | $16.31 +9.5% |
| StockIQ Score | 49D+ Moderate Risk: Medium | 42D Weak Risk: Medium |
| Technical | 45D+ | 36F |
| Fundamental | 30F | 35F |
| Growth | 82A- | 50C- |
| Fair Value | 38F | 38F |
| News | 56C | 50C- |
| Quality | 58C | 50C- |
| Risk | 48D+ | 48D+ |
Scores are based on real financial data only and do not constitute investment advice. How the score is calculated
Xilio Therapeutics (XLO) outperforms Ascentage Pharma (AAPG) in growth and investor confidence, with a growth score of 82 versus 50 and an investor score of 49 compared to 42. However, AAPG has a slightly higher valuation score of 38, matching XLO, while XLO leads in technical and fundamental scores (45 vs. 36, 30 vs. 35). XLO’s overall rating is moderate, while AAPG is weak.
